+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Stage III Non-Small Cell Lung Cancer: Prognostic Value of FDG PET Quantitative Imaging Features Combined with Clinical Prognostic Factors



Stage III Non-Small Cell Lung Cancer: Prognostic Value of FDG PET Quantitative Imaging Features Combined with Clinical Prognostic Factors



Radiology 278(1): 214-222



To determine whether quantitative imaging features from pretreatment positron emission tomography (PET) can enhance patient overall survival risk stratification beyond what can be achieved with conventional prognostic factors in patients with stage III non-small cell lung cancer (NSCLC). The institutional review board approved this retrospective chart review study and waived the requirement to obtain informed consent. The authors retrospectively identified 195 patients with stage III NSCLC treated definitively with radiation therapy between January 2008 and January 2013. All patients underwent pretreatment PET/computed tomography before treatment. Conventional PET metrics, along with histogram, shape and volume, and co-occurrence matrix features, were extracted. Linear predictors of overall survival were developed from leave-one-out cross-validation. Predictive Kaplan-Meier curves were used to compare the linear predictors with both quantitative imaging features and conventional prognostic factors to those generated with conventional prognostic factors alone. The Harrell concordance index was used to quantify the discriminatory power of the linear predictors for survival differences of at least 0, 6, 12, 18, and 24 months. Models were generated with features present in more than 50% of the cross-validation folds. Linear predictors of overall survival generated with both quantitative imaging features and conventional prognostic factors demonstrated improved risk stratification compared with those generated with conventional prognostic factors alone in terms of log-rank statistic (P = .18 vs P = .0001, respectively) and concordance index (0.62 vs 0.58, respectively). The use of quantitative imaging features selected during cross-validation improved the model using conventional prognostic factors alone (P = .007). Disease solidity and primary tumor energy from the co-occurrence matrix were found to be selected in all folds of cross-validation. Pretreatment PET features were associated with overall survival when adjusting for conventional prognostic factors in patients with stage III NSCLC.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058896800

Download citation: RISBibTeXText

PMID: 26176655

DOI: 10.1148/radiol.2015142920


Related references

Further understanding of an uncommon disease of combined small cell lung cancer: clinical features and prognostic factors of 114 cases. Chinese Journal of Cancer Research 28(5): 486-494, 2016

Prognostic factors in clinical stage I non-small cell lung cancer. Annals of Thoracic Surgery 67(4): 927-932, 1999

Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: external validation of a prognostic score. Tumour Biology 29(4): 272-277, 2008

Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach. Journal of BUON 11(1): 31-37, 2007

Late events and clinical prognostic factors in stage I non small cell lung cancer. Lung Cancer 37(2): 171-177, 2002

Limited stage small cell lung cancer: analysis of clinical prognostic factors. Southern Medical Journal 80(12): 1518-1522, 1987

The prognostic impact of combined pulmonary fibrosis and emphysema in patients with clinical stage IA non-small cell lung cancer. Surgery Today 48(2): 229-235, 2017

Prognostic factors in clinical stage T4N2 locally advanced non-small cell lung cancer. Journal of BUON 20(2): 573-579, 2015

Clinical stage I non-small cell lung cancer: An analysis of prognostic factors and a reconsideration of treatments. Lung Cancer 18: 74-75, 1997

Clinical features and prognostic factors of small cell lung cancer: A retrospective study in 148 patients. Journal of Huazhong University of Science and Technology. Medical Sciences 36(6): 916-922, 2017

Stage IIIA and IIIB non-small cell lung cancer: results of chemotherapy combined with radiation therapy and analysis of prognostic factors. Archivos de Bronconeumologia 43(7): 358-365, 2007

Prognostic factors and remote results in operated patients with non-small cell lung cancer in I clinical stage. Khirurgiia 2008(5): 43-44, 2008

Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients. Annals of Oncology 8(6): 547-553, 1997

Prognostic factors in 3315 completely resected cases of clinical stage I non-small cell lung cancer in Japan. Journal of Thoracic Oncology 2(5): 408-413, 2007

Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: analysis of the literature. Lung Cancer 19(1): 3-13, 1998